T-MAXIMUM PHARMACEUTICAL Unveils CAR-T Breakthrough for Solid Tumours
Friday, August 09, 2024
T-MAXIMUM PHARMACEUTICAL, a biotechnology company specialising in universal cell-based therapies, has received international praise for its pioneering work in allogeneic CAR-T cell therapy.
MT027, the lead product in T-MAXIMUM’s pipeline, is an allogeneic CAR-T therapy modified using CRISPR/Cas9 technology to target the B7-H3 tumour antigen in recurrent glioblastoma and other solid tumours. Early studies have shown it to be both effective and safe. MT027 could potentially treat various late-stage solid tumours, offering hope to patients with aggressive cancers.
T-MAXIMUM is preparing MT027 for registration and clinical trials in the United States, with manufacturing already finalised and partnerships established with third-party manufacturers in China and the United States. The product has received Orphan Drug Designation from the US FDA, which could expedite its approval process. In addition to MT027, the company is developing two other allogeneic CAR-T therapies: MT026, targeting IL13Rα2 for solid tumours, and MT020, aimed at treating B-cell related autoimmune diseases.
T-MAXIMUM, has also announced the development of next-generation allogeneic CAR-T therapies for solid tumours, which will involve more advanced T-cell engineering. The company is exploring strategies to combine CAR-T cells with other treatments to improve disease control in advanced solid tumours, ultimately aiming to transform these tumours into manageable chronic conditions.
Traditional CAR-T cell therapies typically use a patient’s own cells, which can be time-consuming and expensive to produce. This method also carries risks, including the potential for manufacturing failures and insufficient T cells in patients who have undergone extensive treatments. In contrast, allogeneic CAR-T therapies use T cells from healthy donors, which are more abundant and functional. This approach allows for the creation of "off-the-shelf" products, offering a more scalable and accessible treatment option.
Solid tumours, which make up about 90% of all cancers, represent a significant unmet medical need, especially in their late stages. While cell therapies have shown success in treating blood cancers, progress in solid tumours has been limited. T-MAXIMUM’s allogeneic CAR-T therapies are designed to enhance effectiveness and overcome rejection issues, making them a promising tool against solid tumours like glioblastoma. Initial clinical trials have shown encouraging results, with the therapy demonstrating a favourable safety profile in over 50 patients.
The company recently presented a trial at the 2024 American Society of Clinical Oncology (ASCO) Breakthrough Summit, focusing on the use of B7H3-specific allogeneic CAR-T cells for treating recurrent high-grade glioma. This study, involving intrathecal or intracerebroventricular administration, was awarded one of only 40 Abstract Awards at the conference.
Source: prnewswire.com
